LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Colorectal Carcinoma Tumor Budding Automatically Evaluated

By LabMedica International staff writers
Posted on 10 Sep 2018
Image: The M8 serves as a dual microscope and scanner with all features accessible via a touch screen computer, making it a truly digital microscope (Photo courtesy of PreciPoint).
Image: The M8 serves as a dual microscope and scanner with all features accessible via a touch screen computer, making it a truly digital microscope (Photo courtesy of PreciPoint).
Tumor budding, meaning a detachment of tumor cells at the invasion front of colorectal carcinoma (CRC) into single cells or clusters has been shown to correlate to an inferior clinical outcome by several independent studies.

However, the application of tumor budding by manual evaluation in routine pathology is hampered due to the use of several slightly different assessment systems, a time-consuming manual counting process and a high inter-observer variability.

Pathologists led by their colleagues at the University Medical Centre Mannheim (Mannheim, Germany) retrieved 20 whole-slide tissue specimens of formalin-fixed paraffin-embedded tumor tissue and tissue microarray (TMAs) of tumor tissue from the Medical University of Graz (Graz, Austria). These cases belong to a previously published patient cohort of 381 patients (166 males, 215 females; median age 70.1 years).

The team combined classical segmentation methods (like morphological operations) and machine learning techniques (k-means and hierarchical clustering, convolutional neural networks) to reliably detect tumor buds in colorectal carcinoma samples immunohistochemically stained for pan-cytokeratin. As a possible application, they tested it on whole-slide images as well as on tissue microarrays (TMA) from the clinically well-annotated CRC cohort. The sequential sections were digitalized as whole-slide images (WSI) using a digital microscope and M8 scanner (PreciPoint GmbH, Freising, Germany).

The scientists reported that their automatic tumor budding evaluation tool detected the absolute number of tumor buds per image with a very good correlation to the manually segmented ground truth. Furthermore the automatic evaluation of whole-slide images from 20 CRC-patients, they found that neither the detected number of tumor buds at the invasion front nor the number in hotspots was associated with the nodal status. However, the number of spatial clusters of tumor buds (budding hotspots) significantly correlated to the nodal status. TMAs were not feasible for tumor budding evaluation, as the spatial relationship of tumor buds (especially hotspots) was not preserved.

The authors concluded that on the basis of a combination of image processing and machine learning, they found that not the absolute number of tumor formations classified as “tumor buds” within the infiltrative region but rather their spatial arrangement in significant hotspots and especially the number of such hotspots is clinically meaningful. Consequently, the advice for the surgical pathologist is to focus more on the spatial distribution (as kind of pattern diagnosis), rather than on the absolute number, of tumor buds. The study was published on August 28, 2018, in the journal Diagnostic Pathology.

Related Links:
University Medical Centre Mannheim
Medical University of Graz
PreciPoint
Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Pipette
Accumax Smart Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more